|
|
|
Transplant Statistics: Annual Report : Reference Tables
| Organ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kidney | PTA | PAK | KP | Liver | Intestine | Heart | Lung | Heart-Lung | |||
| Induction Use (2001 Transplants) | 59.3% | 69.2% | 81.7% | 76.7% | 15.2% | 50.5% | 43.5% | 39.4% | 76.0% | ||
| Induction Drugs (2001 Transplants) | ATG | 2.3% | 0.0% | 0.4% | 2.6% | 0.4% | 0.0% | 7.7% | 8.6% | 28.0% | |
| NRATG/NRATS | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||
| OKT3 | 0.8% | 4.3% | 0.8% | 3.6% | 0.7% | 7.7% | 8.8% | 1.1% | 0.0% | ||
| Thymoglobulin | 17.7% | 54.7% | 54.2% | 28.6% | 2.5% | 14.3% | 11.2% | 5.5% | 12.0% | ||
| Zenapax | 15.0% | 35.9% | 35.9% | 20.6% | 5.9% | 26.4% | 12.7% | 11.3% | 8.0% | ||
| Simulect | 26.0% | 4.3% | 15.3% | 31.8% | 5.9% | 2.2% | 5.2% | 13.5% | 32.0% | ||
| Maintenance At Transplant Discharge (2001 Transplants) | Calcineurin Inhibitor Use | 93.4% | 97.1% | 98.8% | 97.1% | 93.9% | 97.4% | 97.9% | 97.5% | 95.0% | |
| Cyclosporine | 38.7% | 4.8% | 9.6% | 13.7% | 11.9% | 0.0% | 71.2% | 50.6% | 75.0% | ||
| Tacrolimus | 55.3% | 92.4% | 90.8% | 86.5% | 83.0% | 97.4% | 29.2% | 50.5% | 20.0% | ||
| Antimetabolite Use | 80.8% | 68.6% | 78.7% | 82.8% | 50.9% | 10.5% | 91.2% | 92.3% | 95.0% | ||
| Azathioprine | 4.4% | 1.0% | 1.6% | 1.1% | 3.1% | 7.9% | 14.6% | 50.7% | 45.0% | ||
| Mycophenolate mofetil | 77.0% | 67.6% | 77.1% | 82.1% | 47.9% | 2.6% | 78.8% | 42.6% | 50.0% | ||
| Rapamycin Use | 17.0% | 12.4% | 22.1% | 18.7% | 9.7% | 14.5% | 4.4% | 3.8% | 0.0% | ||
| Current Maintenance At End of First Year (2000 Transplants) | Calcineurin Inhibitor Use | 90.5% | 87.8% | 93.4% | 92.7% | 91.4% | 95.3% | 92.9% | 92.2% | 92.9% | |
| Cyclosporine | 44.6% | 4.4% | 13.6% | 18.5% | 19.0% | 0.0% | 66.3% | 41.8% | 35.7% | ||
| Tacrolimus | 46.2% | 83.3% | 80.3% | 75.6% | 74.4% | 95.3% | 27.2% | 50.6% | 57.1% | ||
| Antimetabolite Use | 72.7% | 72.2% | 71.2% | 77.3% | 28.0% | 7.0% | 83.2% | 80.2% | 71.4% | ||
| Azathioprine | 5.6% | 5.6% | 4.0% | 3.7% | 3.4% | 0.0% | 12.2% | 38.8% | 32.1% | ||
| Mycophenolate mofetil | 67.6% | 66.7% | 67.7% | 74.6% | 24.8% | 7.0% | 71.1% | 41.8% | 42.9% | ||
| Rapamycin Use | 12.7% | 18.9% | 22.2% | 16.1% | 9.6% | 27.9% | 3.6% | 5.4% | 7.1% | ||
Center-Specific Reports | OPO Reports | National Reports | Data Accuracy | Report Timeline
Home | Who We Are | What We Do | About Transplants | Transplant Statistics | Research Resources | Contact Us | Site Map
SRTR Site designed and maintained by Diamond Bullet Design & URREA.